Lexaria Bioscience Corp

Lexaria Bioscience signs 10 year agreement with Hill Street Beverage

Lexaria Bioscience (CSE: LXX) President and CEO Chris Bunka joined Steve Darling from Proactive Investors Vancouver to talk about the company agreeing to a 10-year deal that will see Hill Street using Leaxraia's DehydraTech technology to infuse beverages and other products.

Bunka telling Proactive how the deal will work and what markets this new deal will open to both companies.

Quick facts: Lexaria Bioscience Corp

Price: $0.94

Market: CSE
Market Cap: $73.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company...



Full interview: Lexaria Bioscience ChrgD up about CBD product launch in the U.S.

Lexaria BioScience (CSE: LXX-OTCQX-LXRP) CEO Chris Bunka joined Steve Darling from Proactive Canada to discuss the company launching a new product featuring hemp oil in a powdered format.  Bunka talks about ChrgD and why this product can demonstrate Lexaria's ability to deliver CBD into...

3 weeks, 6 days ago

2 min read